{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:16:35Z","timestamp":1789193795013,"version":"build-2803163510"},"reference-count":107,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1097\/md.0000000000008719","type":"journal-article","created":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T22:05:35Z","timestamp":1511906735000},"page":"e8719","source":"Crossref","is-referenced-by-count":21,"title":["A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis"],"prefix":"10.1097","volume":"96","author":[{"given":"Sandra","family":"Korol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fannie","family":"Mottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Perreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"de Denus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-26-20210226","doi-asserted-by":"crossref","first-page":"689360","DOI":"10.1155\/2014\/689360","article-title":"The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling","volume":"2014","author":"Pacurari","year":"2014","journal-title":"Int J Inflam"},{"key":"R2-26-20210226","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1001\/jama.2014.5180","article-title":"Resistant hypertension: a review of diagnosis and management","volume":"311","author":"Vongpatanasin","year":"2014","journal-title":"JAMA"},{"key":"R3-26-20210226","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R4-26-20210226","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-26-20210226","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R6-26-20210226","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"R7-26-20210226","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.suc.2014.02.007","article-title":"Hyperaldosteronism: diagnosis, lateralization, and treatment","volume":"94","author":"Harvey","year":"2014","journal-title":"Surg Clin North Am"},{"key":"R8-26-20210226","first-page":"2111","article-title":"Treatment of edema","volume":"71","author":"O\u2019Brien","year":"2005","journal-title":"Am Fam Physician"},{"key":"R9-26-20210226","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1524-6175.2004.3735.x","article-title":"Gynecomastia and antihypertensive therapy","volume":"6","author":"Mosenkis","year":"2004","journal-title":"J Clin Hypertens"},{"key":"R10-26-20210226","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1524-6175.2005.04105.x","article-title":"Gynecomastia and hypertension","volume":"7","author":"Prisant","year":"2005","journal-title":"J Clin Hypertens"},{"key":"R11-26-20210226","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1248\/bpb.26.695","article-title":"Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17","volume":"26","author":"Satoh","year":"2003","journal-title":"Biol Pharma Bull"},{"key":"R12-26-20210226","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/1871530311313010015","article-title":"Managing erectile dysfunction in heart failure","volume":"13","author":"Giagulli","year":"2013","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"R13-26-20210226","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40257-014-0078-4","article-title":"Hirsutism: an evidence-based treatment update","volume":"15","author":"Somani","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"R14-26-20210226","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4158\/EP15748.DSC","article-title":"American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and Pcos Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome\u2014Part 1","volume":"21","author":"Goodman","year":"2015","journal-title":"Endocr Pract"},{"key":"R15-26-20210226","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1210\/jcem-67-4-824","article-title":"Adrenocorticotropin and cortisol-induced changes in urinary sodium and potassium excretion in man: effects of spironolactone and RU486","volume":"67","author":"Clore","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-26-20210226","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.metabol.2012.08.011","article-title":"Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males","volume":"62","author":"Krug","year":"2013","journal-title":"Metabolism"},{"key":"R17-26-20210226","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.HYP.2.5.672","article-title":"Clinical and biochemical effects of spironolactone administered once daily in primary hypertension. Multicenter Sweden study","volume":"2","author":"Schersten","year":"1980","journal-title":"Hypertension"},{"key":"R18-26-20210226","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/ajh\/4.4.356","article-title":"Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty?","volume":"4","author":"Plouin","year":"1991","journal-title":"Am J Hypertens"},{"key":"R19-26-20210226","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/HYPERTENSIONAHA.112.194787","article-title":"Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients","volume":"60","author":"Raheja","year":"2012","journal-title":"Hypertension"},{"key":"R20-26-20210226","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2008-2660","article-title":"Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients","volume":"94","author":"Menon","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-26-20210226","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/archinte.1984.00350160058010","article-title":"Serum cholesterol during treatment of hypertension with diuretic drugs","volume":"144","author":"Ames","year":"1984","journal-title":"Arch Intern Med"},{"key":"R22-26-20210226","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3109\/10641960903407017","article-title":"Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker","volume":"31","author":"Yutaka","year":"2009","journal-title":"Clin Exp Hypertens"},{"key":"R23-26-20210226","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpt197925133","article-title":"Hydrochlorothiazide and spironolactone in hypertension","volume":"25","author":"Schrijver","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"R24-26-20210226","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.0954-6820.1983.tb03684.x","article-title":"The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives","volume":"213","author":"Falch","year":"1983","journal-title":"Acta Med Scand"},{"key":"R25-26-20210226","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/0002-9149(88)90551-6","article-title":"Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension","volume":"62","author":"Jeunemaitre","year":"1988","journal-title":"Am J Cardiol"},{"key":"R26-26-20210226","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"key":"R27-26-20210226","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"R28-26-20210226","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/jhh.2014.19","article-title":"Effect of eplerenone on insulin action in essential hypertension: a randomised, controlled, crossover study","volume":"28","author":"McMurray","year":"2014","journal-title":"J Hum Hypertens"},{"key":"R29-26-20210226","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/1470320310390404","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study","volume":"12","author":"Yano","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R30-26-20210226","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/jhh.2009.81","article-title":"Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension","volume":"24","author":"Sato","year":"2010","journal-title":"J Hum Hypertens"},{"key":"R31-26-20210226","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/dom.12224","article-title":"Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects","volume":"16","author":"Garg","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R32-26-20210226","first-page":"2198","article-title":"Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women\u2014a clinical research center study","volume":"81","author":"Lovejoy","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-26-20210226","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"R34-26-20210226","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1751-7176.2010.00339.x","article-title":"Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome","volume":"12","author":"Costa","year":"2010","journal-title":"J Clin Hypertens"},{"key":"R35-26-20210226","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1590\/S0101-28002011000400012","article-title":"Espironolactone improves flow-mediated vasodilatation in subjects with the metabolic syndrome","volume":"33","author":"Lovisi","year":"2011","journal-title":"J Bras Nefrol"},{"key":"R36-26-20210226","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diabet.2015.10.005","article-title":"Effect of low-dose mineralocorticoid receptor antagonists on metabolic profile and endothelial dysfunction in metabolic syndrome","volume":"42","author":"Kanchan","year":"2016","journal-title":"Diabetes Metab"},{"key":"R37-26-20210226","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1089\/met.2015.0044","article-title":"Effect of selective mineralocorticoid receptor blockade on flow-mediated dilation and insulin resistance in older adults with metabolic syndrome","volume":"13","author":"Hwang","year":"2015","journal-title":"Metab Syndr Relat Disord"},{"key":"R38-26-20210226","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1517\/14656566.2013.832756","article-title":"Effects of canrenone in patients with metabolic syndrome","volume":"14","author":"Derosa","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"R39-26-20210226","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/07853890.2014.969303","article-title":"The effects of canrenone on inflammatory markers in patients with metabolic syndrome","volume":"47","author":"Derosa","year":"2015","journal-title":"Ann Med"},{"key":"R40-26-20210226","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00125-008-0972-5","article-title":"Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles","volume":"51","author":"Swaminathan","year":"2008","journal-title":"Diabetologia"},{"key":"R41-26-20210226","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","article-title":"Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes","volume":"47","author":"Davies","year":"2004","journal-title":"Diabetologia"},{"key":"R42-26-20210226","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study","volume":"29","author":"Nielsen","year":"2012","journal-title":"Diabet Med"},{"key":"R43-26-20210226","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"R44-26-20210226","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"R45-26-20210226","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"R46-26-20210226","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial","volume":"31","author":"Oxlund","year":"2013","journal-title":"J Hypertens"},{"key":"R47-26-20210226","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"R48-26-20210226","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1210\/jc.2005-1718","article-title":"Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy","volume":"91","author":"Takebayashi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R49-26-20210226","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.metabol.2006.07.025","article-title":"The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy","volume":"55","author":"Matsumoto","year":"2006","journal-title":"Metabolism"},{"key":"R50-26-20210226","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R51-26-20210226","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2337\/db14-0670","article-title":"Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes","volume":"64","author":"Garg","year":"2015","journal-title":"Diabetes"},{"key":"R52-26-20210226","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1470320313481485","article-title":"Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy","volume":"16","author":"Momeni","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R53-26-20210226","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2215\/CJN.06330612","article-title":"Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes","volume":"8","author":"Viswanathan","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R54-26-20210226","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1681\/ASN.2006060606","article-title":"Effect of various diuretic treatments on rosiglitazone-induced fluid retention","volume":"17","author":"Karalliedde","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R55-26-20210226","doi-asserted-by":"crossref","first-page":"985","DOI":"10.4158\/EP.14.8.985","article-title":"Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors","volume":"14","author":"Davidson","year":"2008","journal-title":"Endocr Pract"},{"key":"R56-26-20210226","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R57-26-20210226","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1210\/jc.2007-0393","article-title":"Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus","volume":"92","author":"Joffe","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R58-26-20210226","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3109\/10641963.2016.1151526","article-title":"Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus","volume":"38","author":"Karashima","year":"2016","journal-title":"Clin Exp Hypertens"},{"key":"R59-26-20210226","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1517\/14656566.2014.874415","article-title":"Comparative effect of canrenone or hydrochlorothiazide addition to valsartan\/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria","volume":"15","author":"Fogari","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"R60-26-20210226","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ijcard.2013.12.039","article-title":"Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure","volume":"171","author":"Ogino","year":"2014","journal-title":"Int J Cardiol"},{"key":"R61-26-20210226","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2337\/dc08-1709","article-title":"Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program","volume":"32","author":"Preiss","year":"2009","journal-title":"Diabetes Care"},{"key":"R62-26-20210226","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurjhf\/hfs067","article-title":"Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"14","author":"Preiss","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"R63-26-20210226","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.cardfail.2012.03.002","article-title":"Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS","volume":"18","author":"Ukena","year":"2012","journal-title":"J Card Fail"},{"key":"R64-26-20210226","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1)(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"key":"R65-26-20210226","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1210\/jc.2013-1040","article-title":"Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study","volume":"98","author":"Ganie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R66-26-20210226","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.contraception.2011.12.011","article-title":"The effects of 2\u200amg chlormadinone acetate\/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome","volume":"86","author":"Vieira","year":"2012","journal-title":"Contraception"},{"key":"R67-26-20210226","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.numecd.2013.04.016","article-title":"In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone","volume":"24","author":"Mazza","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R68-26-20210226","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00404-009-1051-y","article-title":"Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome","volume":"281","author":"Kebapcilar","year":"2010","journal-title":"Arch Gynecol Obstet"},{"key":"R69-26-20210226","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/09513590.2015.1080679","article-title":"Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome","volume":"32","author":"Diri","year":"2016","journal-title":"Gynecol Endocrinol"},{"key":"R70-26-20210226","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00404-009-1189-7","article-title":"Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients","volume":"281","author":"Kebapcilar","year":"2010","journal-title":"Arch Gynecol Obstet"},{"key":"R71-26-20210226","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/dc06-0618","article-title":"Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome","volume":"30","author":"Meyer","year":"2007","journal-title":"Diabetes Care"},{"key":"R72-26-20210226","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1530\/EJE-10-0709","article-title":"Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome","volume":"164","author":"Studen","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"R73-26-20210226","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2009.03483.x","article-title":"Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism","volume":"68","author":"Nakhjavani","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R74-26-20210226","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0015-0282(16)47716-2","article-title":"The influence of androgens on insulin resistance","volume":"41","author":"Shoupe","year":"1984","journal-title":"Fertil Steril"},{"key":"R75-26-20210226","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF03345529","article-title":"Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile","volume":"28","author":"Zulian","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"R76-26-20210226","first-page":"952","article-title":"The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women","volume":"81","author":"Moghetti","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"R77-26-20210226","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0010-7824(91)90112-S","article-title":"Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone","volume":"44","author":"Wild","year":"1991","journal-title":"Contraception"},{"key":"R78-26-20210226","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3109\/09513590.2012.671394","article-title":"Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome\u2014a retrospective analysis","volume":"28","author":"Kulshreshtha","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"R79-26-20210226","first-page":"21","article-title":"Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment","volume":"108","author":"Sindelka","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R80-26-20210226","doi-asserted-by":"crossref","first-page":"503","DOI":"10.33549\/physiolres.930298","article-title":"Does the treatment of primary hyperaldosteronism influence glucose tolerance?","volume":"52","author":"Strauch","year":"2003","journal-title":"Physiol Res"},{"key":"R81-26-20210226","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1210\/jc.2006-0736","article-title":"Insulin sensitivity in patients with primary aldosteronism: a follow-up study","volume":"91","author":"Catena","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R82-26-20210226","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1097\/HJH.0b013e3282861fa4","article-title":"A possible association between primary aldosteronism and a lower beta-cell function","volume":"25","author":"Mosso","year":"2007","journal-title":"J Hypertens"},{"key":"R83-26-20210226","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2014.348","article-title":"Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans","volume":"87","author":"Hosoya","year":"2015","journal-title":"Kidney Int"},{"key":"R84-26-20210226","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1523-1755.2004.00931.x","article-title":"Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients","volume":"66","author":"Michea","year":"2004","journal-title":"Kidney Int"},{"key":"R85-26-20210226","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/jmv.21572","article-title":"Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C","volume":"81","author":"Arase","year":"2009","journal-title":"J Med Virol"},{"key":"R86-26-20210226","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/1470320311402110","article-title":"Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease","volume":"12","author":"Polyzos","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R87-26-20210226","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s40265-013-0098-z","article-title":"Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms","volume":"73","author":"Dhillon","year":"2013","journal-title":"Drugs"},{"key":"R88-26-20210226","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-012-9370-7","article-title":"Co-morbidities in heart failure","volume":"19","author":"van Deursen","year":"2014","journal-title":"Heart Fail Rev"},{"key":"R89-26-20210226","doi-asserted-by":"crossref","first-page":"e42551","DOI":"10.1371\/journal.pone.0042551","article-title":"Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2012","journal-title":"PloS One"},{"key":"R90-26-20210226","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1001\/archinte.168.15.1699","article-title":"The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program","volume":"168","author":"Gerstein","year":"2008","journal-title":"Arch Intern Med"},{"key":"R91-26-20210226","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R92-26-20210226","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R93-26-20210226","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/14656566.2014.896901","article-title":"Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs","volume":"15","author":"Armanini","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"R94-26-20210226","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2337\/diacare.28.9.2261","article-title":"The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes","volume":"28","author":"Gillespie","year":"2005","journal-title":"Diabetes Care"},{"key":"R95-26-20210226","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jash.2016.05.013","article-title":"Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Zhao","year":"2016","journal-title":"J Am Soc Hypertens"},{"key":"R96-26-20210226","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann Intern Med"},{"key":"R97-26-20210226","first-page":"337","article-title":"Cortisol metabolism in hypertension. Best practice & research","volume":"20","author":"Hammer","year":"2006","journal-title":"Clin Endocrinol Metab"},{"key":"R98-26-20210226","first-page":"3339","article-title":"The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans","volume":"83","author":"Young","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"R99-26-20210226","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1210\/jc.2009-0370","article-title":"Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis","volume":"94","author":"Anagnostis","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R100-26-20210226","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2337\/dc06-1267","article-title":"Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications","volume":"30","author":"Chiodini","year":"2007","journal-title":"Diabetes Care"},{"key":"R101-26-20210226","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11906-014-0443-y","article-title":"Hypercortisolism in obesity-associated hypertension","volume":"16","author":"Varughese","year":"2014","journal-title":"Curr Hypertens Rep"},{"key":"R102-26-20210226","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1161\/CIRCHEARTFAILURE.109.868513","article-title":"Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress","volume":"2","author":"Yamaji","year":"2009","journal-title":"Circ Heart Fail"},{"key":"R103-26-20210226","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/dmrr.2262","article-title":"Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing's syndrome?","volume":"28","author":"Krarup","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"R104-26-20210226","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cardfail.2008.12.011","article-title":"Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure","volume":"15","author":"Jankowska","year":"2009","journal-title":"J Card Fail"},{"key":"R105-26-20210226","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/eurjhf\/hfq108","article-title":"Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure","volume":"12","author":"Jankowska","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"R106-26-20210226","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4103\/2230-8229.122006","article-title":"Prevalence of low testosterone levels in men with type 2 diabetes mellitus: a cross-sectional study","volume":"20","author":"Al Hayek","year":"2013","journal-title":"J Family Community Med"},{"key":"R107-26-20210226","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1530\/JOE-13-0393","article-title":"Testosterone and glucose metabolism in men: current concepts and controversies","volume":"220","author":"Grossmann","year":"2014","journal-title":"J Endocrinol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T12:28:03Z","timestamp":1693312083000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201712010-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":107,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008719","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}